5-乙氧基吡啶-2-羧酸甲酯 | 941306-58-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-乙氧基吡啶-2-羧酸甲酯
• 英文名称: methyl 5-ethoxypicolinate
• 英文别名: Methyl 5-ethoxypicolinate；methyl 5-ethoxypyridine-2-carboxylate
• CAS: 941306-58-7
• 化学式: C₉H₁₁NO₃
• 分子量: 181.191
• InChiKey: XTKIKIRJBDIXAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  5-乙氧基吡啶-2-羧酸甲酯 在 甲醇 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以72.3%的产率得到5-乙氧基-2-吡啶羧酸
  参考文献：
  名称：

  [EN] IMMUNOREGULATORY AGENTS
  [FR] AGENTS IMMUNORÉGULATEURS

  摘要：

  公开号：

  WO2016073774A3
• 作为产物：
  描述：

  2-乙氧基丙-2-烯醛 在 potassium carbonate 、 对苯二酚 作用下， 以 乙醚 、 苯 为溶剂， 反应 2568.35h， 生成 5-乙氧基吡啶-2-羧酸甲酯
  参考文献：
  名称：

  Synthesis of 2-ethoxyprop-2-enal dimethylhydrazone and its Diels-Alder reactions

  摘要：

  Conditions were found for the preparation of 2-ethoxyprop-2-enal dimethylhydrazone by reaction of 2-ethoxypropenal with N,N-dimethylhydrazine. 2-Ethoxyprop-2-enal dimethylhydrazone reacted with methyl vinyl ketone and methyl acrylate according to the [4+2]-cycloaddition pattern with regioselective formation of substituted tetrahydropyridines. The major product in the reaction of 2-ethoxyprop-2-enal dimethylhydrazone with 1,4-benzoquinone was 5-hydroxy-1-benzofuran-2-carbaldehyde dimethylhydrazone formed as a result of [3+2]-cycloaddition; a small amount of the corresponding [4+2]-cycloaddition product was also obtained. Some spontaneous transformations of the primary cycloaddition products were revealed.

  DOI：

  10.1134/s1070428006100010

文献信息

• 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
  申请人：上海赛默罗生物科技有限公司

  公开号：CN112979655A

  公开（公告）日：2021-06-18

  本发明涉及三唑并哒嗪类衍生物、其制备方法、药物组合物和用途。本发明提供一种通式(I)所示的化合物、其顺反异构体、其对映异构体、其非对映异构体、其外消旋体、其溶剂合物、其水合物或其药学上可以接受的盐或其前体药物，其制备方法，含有该化合物的药物组合物以及所述化合物作为α5‑GABAA受体调节剂的用途，其中R1，R2和Z如说明书中所定义。
• PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
  申请人：AMGEN INC.

  公开号：US20140249104A1

  公开（公告）日：2014-09-04

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , each of R 1 and R 2 , R 3 and R 7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.

  本发明提供了一类新的化合物，用于调节β-分泌酶（BACE）活性。这些化合物的通用公式为I： 其中变量A4，A5，A6，A8，公式I中的R1和R2，R3和R7各自独立定义如下。本发明还提供了包含这些化合物的药物组合物，以及使用这些化合物和组合物治疗与A-β斑块形成和沉积相关的疾病和/或状况，这些疾病和/或状况是由BACE的生物活性引起的。这样的BACE介导的疾病包括，例如，阿尔茨海默病，认知缺陷，认知障碍，精神分裂症和其他中枢神经系统疾病。本发明进一步提供了公式II和III的化合物，以及其子公式的实施例，中间体和用于制备公式I-III化合物的过程和方法。
• Compounds and their use as BACE Inhibitors
  申请人：Csjernyik Gabor

  公开号：US20120165347A1

  公开（公告）日：2012-06-28

  The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

  本发明涉及式(I)的化合物及其药物组合物。此外，本发明涉及治疗方法，用于治疗和/或预防与Aβ相关的病理，如唐氏综合症，β-淀粉样蛋白血管病，如但不限于脑淀粉样蛋白血管病或遗传性脑出血，与认知损害相关的疾病，如但不限于MCI（“轻度认知损害”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与疾病如阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合性血管性和退行性起源的痴呆，早老性痴呆，老年性痴呆和与帕金森病、进行性上核性麻痹或皮层基底节变性相关的痴呆。
• [EN] COMPOUNDS AND THEIR USE AS BACE INHIBITORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE BACE
  申请人：ASTRAZENECA AB

  公开号：WO2012087237A1

  公开（公告）日：2012-06-28

  The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Αβ-related pathologies such as Down's syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.

  本发明涉及公式（I）化合物及其制药组合物。此外，本发明涉及治疗和/或预防与Αβ相关的病理学，如唐氏综合症，β-淀粉样血管病，如但不限于脑淀粉样血管病或遗传性脑出血，与认知障碍相关的疾病，如但不限于轻度认知障碍（MCI），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与阿尔茨海默病或痴呆症等疾病相关的神经退行性。包括混合血管性和退行性起源的痴呆症，早老性痴呆症，老年痴呆症和与帕金森病相关的痴呆症的治疗方法。
• TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS
  申请人：Holsworth Daniel

  公开号：US20140031374A1

  公开（公告）日：2014-01-30

  The present invention relates to compounds of formula (I), to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy: Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway and increased presence of nuclear β-catenin. For example, these may be used in preventing and/or retarding proliferation of tumor cells and metastasis, for example carcinomas such as colon carcinomas.

  本发明涉及式(I)的化合物、制备它们的方法、含有这种化合物的药物配方以及它们在治疗中的应用。这些化合物在治疗和/或预防受Wnt通路信号过度激活和核β-连环蛋白存在增加影响的疾病或病症方面具有特殊用途。例如，它们可用于预防和/或延缓肿瘤细胞和转移的增殖，例如结肠癌等癌症。